Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more
Peptron Inc - Asset Resilience Ratio
Peptron Inc (087010) has an Asset Resilience Ratio of 57.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Peptron Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Peptron Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩105.49 Billion | 57.41% |
| Total Liquid Assets | ₩105.49 Billion | 57.41% |
Asset Resilience Insights
- Very High Liquidity: Peptron Inc maintains exceptional liquid asset reserves at 57.41% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Peptron Inc Industry Peers by Asset Resilience Ratio
Compare Peptron Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
Annual Asset Resilience Ratio for Peptron Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Peptron Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 72.74% | ₩122.85 Billion | ₩168.89 Billion | +71.37pp |
| 2023-12-31 | 1.37% | ₩718.34 Million | ₩52.50 Billion | -23.89pp |
| 2022-12-31 | 25.26% | ₩17.24 Billion | ₩68.27 Billion | -13.57pp |
| 2021-12-31 | 38.83% | ₩30.24 Billion | ₩77.87 Billion | -21.15pp |
| 2020-12-31 | 59.98% | ₩70.59 Billion | ₩117.70 Billion | +31.21pp |
| 2019-12-31 | 28.77% | ₩17.55 Billion | ₩60.99 Billion | -8.57pp |
| 2018-12-31 | 37.34% | ₩26.80 Billion | ₩71.76 Billion | +6.92pp |
| 2017-12-31 | 30.42% | ₩16.14 Billion | ₩53.05 Billion | -31.32pp |
| 2016-12-31 | 61.75% | ₩35.75 Billion | ₩57.90 Billion | +61.31pp |
| 2015-12-31 | 0.43% | ₩94.00 Million | ₩21.66 Billion | -0.38pp |
| 2014-12-31 | 0.81% | ₩94.00 Million | ₩11.58 Billion | -- |